Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Lineage Cell Therapeutics, Inc. (Symbol: LCTX) is a clinical-stage biotechnology company that is pioneering the development and commercialization of novel therapies designed to address degenerative diseases. With a foundation built on pluripotent cell technology, Lineage Cell's innovative approach leverages cells capable of transforming into any type of cell in the human body. This groundbreaking capability allows for therapies aimed at regenerating or replacing damaged cells and tissues, providing hope for conditions that currently have no cure.
The company's pipeline is robust and diverse, encompassing several key product candidates:
- OpRegen: A retinal pigment epithelium transplant therapy targeting dry age-related macular degeneration, a leading cause of vision loss among the elderly.
- OPC1: An oligodendrocyte progenitor cell therapy designed to treat acute spinal cord injuries by promoting cell replacement and recovery.
- VAC2: An allogeneic cancer immunotherapy utilizing antigen-presenting dendritic cells to fight non-small cell lung cancer.
- ANP1: A promising therapy involving the transplant of allogeneic auditory neuron progenitor cells to combat hearing loss.
- PNC1: An innovative approach using allogeneic photoreceptor cell transplants aimed at treating vision loss.
Lineage Cell Therapeutics is committed to addressing large unmet medical needs through its cutting-edge technologies. The company's clinical-stage programs are supported by a premier collection of pluripotent cell assets, positioning it at the forefront of regenerative medicine.
Recent achievements include significant progress in clinical trials, strategic partnerships, and advancements in their product development pipeline. Financially, the company remains poised for growth with a clear focus on expanding its therapeutic offerings and enhancing shareholder value.
Stay informed with the latest updates and developments at Lineage Cell Therapeutics as they continue to advance their mission of transforming the treatment landscape for degenerative diseases.
Lineage Cell Therapeutics announced a $50 million upfront payment from Genentech as part of a collaboration for the development of OpRegen, a cell therapy targeting advanced dry AMD with GA. The total potential payment could reach $670 million, including milestone payments and royalties. Genentech will lead further clinical development, while Lineage will complete current studies and manufacturing tasks. This partnership aims to leverage Genentech's expertise to expedite OpRegen's clinical progress and commercialization.
Lineage Cell Therapeutics (LCTX) announced significant findings from its OpRegen Phase 1/2a clinical study, reporting retinal tissue restoration in four patients with dry age-related macular degeneration (AMD). The areas of geographic atrophy diminished or remained stable over 12 months, and all patients exhibited improvements in visual acuity. Statistically significant differences in visual acuity between treated and untreated eyes were observed at 9, 12, and 15 months. Lineage plans to engage with the FDA regarding OpRegen's development, which has been well tolerated without serious adverse events reported.
Lineage Cell Therapeutics reported positive interim results from its Phase 1/2a clinical trial of OpRegen, a therapy for dry age-related macular degeneration (AMD). Over 12 months, patients in Cohort 4 showed significant improvements in retinal restoration and visual acuity. Specifically, 58% of these patients maintained or improved their vision compared to 67% of untreated eyes. The treatment has been well tolerated, with no new adverse events reported. Lineage plans to engage with the FDA regarding future trials in early 2022.
Lineage Cell Therapeutics (LCTX) reported third quarter 2021 financials, highlighting ongoing clinical advancements in its OpRegen program for dry AMD. Key achievements include positive interim outcomes in 67% of treated patients and a new delivery device for OPC1 trials underway. The company holds $65.1 million in cash and marketable securities. Total revenues rose to $2.3 million, driven by a $1.6 million increase in royalty revenues. Operating expenses totaled $8.1 million. Despite a net loss of $7.8 million, the company is preparing for FDA engagement and clinical trials slated for Q4 2021 and Q1 2022.
Lineage Cell Therapeutics (AMEX:LCTX) is set to report its third quarter 2021 financial and operating results on November 10, 2021, after U.S. market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide business updates. Lineage specializes in allogeneic cell therapies targeting significant unmet medical needs, with three key product candidates in development for conditions such as dry age-related macular degeneration and acute spinal cord injuries, presenting billion-dollar market opportunities.
Lineage Cell Therapeutics (LCTX) announced updated interim results from its Phase 1/2a clinical study of OpRegen®, targeting dry age-related macular degeneration (AMD). The study presentation will occur at the 2021 American Academy of Ophthalmology meeting on November 13, 2021. OpRegen has shown ability to halt or reverse geographic atrophy and restore retinal tissue in three patients. The presentation will include data from 24 patients with a minimum 12-month follow-up, highlighting improved baseline vision in the latest cohort.
Lineage Cell Therapeutics (LCTX) announces participation in a fireside chat hosted by B. Riley Securities on
Lineage Cell Therapeutics announced statistically significant interim results from its Phase 1/2a study of OpRegen for treating dry age-related macular degeneration (AMD). After 9 to 15 months of follow-up, patients receiving OpRegen showed improved visual acuity compared to untreated eyes, with p-values indicating significance (P = 0.0085 at 9 months). The therapy was well tolerated, with no new adverse effects reported. The results suggest potential for OpRegen to address unmet needs in AMD treatment.
Lineage Cell Therapeutics, a clinical-stage biotechnology firm focused on allogeneic cell therapies, announced that CEO Brian M. Culley will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 27 at 4pm ET. Interested parties can register for both live and on-demand presentations on the company's website. Lineage is developing three main products: OpRegen, OPC1, and VAC2, targeting significant health issues like dry age-related macular degeneration and non-small cell lung cancer.
Lineage Cell Therapeutics reported interim results from its Phase 1/2a study of OpRegen, a cell therapy for dry age-related macular degeneration (AMD). Key findings include:
- Zero growth of retinal atrophy in one patient after 33 months.
- 10% reduction in atrophy size noted at 8 months in another patient.
- Average visual acuity improvement of 10.8 letters in treated versus untreated eyes.
OpRegen has shown strong tolerability with no unexpected adverse events, suggesting potential for significant therapeutic outcomes.
FAQ
What is the current stock price of Lineage Cell Therapeutics (LCTX)?
What is the market cap of Lineage Cell Therapeutics (LCTX)?
What does Lineage Cell Therapeutics, Inc. specialize in?
What are the main product candidates of Lineage Cell Therapeutics?
What is OpRegen?
How does Lineage Cell Therapeutics utilize pluripotent cells?
What is OPC1 designed to treat?
What type of cancer is VAC2 targeting?
What recent achievements has Lineage Cell Therapeutics made?
What is ANP1?
What is the financial outlook of Lineage Cell Therapeutics?
Where can I find the latest updates on Lineage Cell Therapeutics?
